- Clinical trial STAY tests LOY-002 to extend senior dogs' lifespan and healthspan
- LOY-002 targets metabolic dysfunction to prevent ageing-related damage proactively
- Dogs age faster than humans, making them ideal subjects for longevity research
If you've ever looked into the greying muzzle of your dog and wished for just a few more years, you aren't alone. For most pet parents, the "dog years" trade-off is the cruellest part of the companion animal bond. But what if people could actually slow down the ticking clock? Right now, 1,300 dogs across the United States are participating in a history-making clinical trial that could change the definition of ageing. This isn't science fiction; it is the STAY study, a massive four-year trial testing a drug called LOY-002, designed to help senior dogs live longer, healthier lives.
Globally, around 500 million pet dogs exist that can get a new lease on life should the drug become available for safe use. While in India, 10.2 million dogs exist that can benefit from this drug, which can not only slow down ageing but also improve susceptibility to age-related ailments. The access to quality medical care is also an issue that impacts the quality of healthcare that dogs receive, which makes this drug show promise in the right direction.
The Science Of Dogs Staying Young
The drug, developed by the biotech firm Loyal, has recently cleared a massive regulatory hurdle. The US FDA has officially accepted the Target Animal Safety (TAS) portion of Loyal's application. The data from over 400 dogs suggests the drug is safe for its intended use.
Unlike traditional medicine that waits for a disease like arthritis or kidney failure to strike, LOY-002 takes a proactive approach. It targets metabolic dysfunction, the cellular "wear and tear" that naturally occurs as a dog ages.
"Their goal is to prevent the harm of ageing before it happens," says Celine Halioua, founder and CEO of Loyal. "This brings us one step closer to the first-ever FDA-approved drug for lifespan extension."
Why Dogs?
You might wonder why we are solving ageing for dogs before humans. The answer is simple: dogs are the perfect biological "mirror" for us. They live in homes, breathe the same air, and suffer from the same age-related ailments, from cognitive decline to cancer. Because they age roughly seven times faster than humans, scientists can see the results of longevity treatments in years rather than decades.
The STAY study is a double-blind, placebo-controlled trial. This means half the 1,300 dogs receive the daily pill, and the other half receive a placebo. Neither the parents nor the vets know which is which, ensuring the results are scientifically "gold standard".
Also Read: Why Getting Your Dog Vaccinated Against Rabies And Other Diseases Is Critical
The Multi-Front War On Ageing
Loyal isn't just stopping at senior dogs. They are attacking the longevity problem from three different angles:
1. LOY-002 (The STAY Study): A daily pill for senior dogs (10+ years old) of almost all sizes to improve metabolic health.
2. LOY-001: A long-acting injectable specifically for large and giant breeds (like Great Danes or Golden Retrievers). Large dogs often have higher levels of IGF-1, a growth hormone that helps them get big but also accelerates their ageing. LOY-001 aims to lower this hormone to "small dog" levels.
3. LOY-003: A daily pill version of the large-dog longevity treatment.
What Does This Mean For Your Pet?
If LOY-002 receives conditional approval, it could be available at veterinary clinics as early as late 2026. The drug aims not just to tack on extra months but to extend the "healthspan", the period of life where your dog is active, alert, and pain-free.
For the pet parents currently in the trial, like the parent of 13-year-old Labrador Bella, the hope is palpable. While the trial is still ongoing, many participants report seeing a "spark" return to their senior dogs with more energy during walks and a renewed interest in play.
This is a paradigm shift in the current state of dog healthcare. Ageing is no longer being viewed as an inevitable "falling apart" but as a biological condition that can be managed. As people wait for the final results of the 1,300-dog trial, one thing is clear: the bridge between "youth" and "old age" is getting a lot sturdier.
Disclaimer: This content, including advice, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
